Plasma Adipokine and Hormone Changes in Mountaineers on Ascent to 5300 Meters

ObjectiveThe current study evaluated multiple metabolic and inflammatory hormone responses in recreational climbers (7 men and 3 women, age 26–49 years) over 9 days. In particular, acylation-stimulating protein (ASP), which influences fat storage in adipose tissue, has not been measured at high altitude.MethodsSerial measurements were taken at sea level (SL), or 353 m, on day 0, 4000 m on day 3, 4750 m on day 6, and 5300 m on day 9 of the expedition.ResultsBody mass index (BMI) decreased upon ascent to 5300 m from SL (SL 23.2 ± 1.5 kg/m2; 4000 m 23.2 ± 1.4 kg/m2; 4750 m 22.9 ± 1.3 kg/m2; 5300 m 22.3 ± 1.2 kg/m2; P < .001). Similarly, plasma non-esterified fatty acids and triglycerides increased, while HDL cholesterol decreased (P < .05 to < .001) from SL to 5300 m. Acylation-stimulating protein (SL 42.2 ± 40.2 nm; 4000 m 117.0 ± 69.6 nm; 4750 m 107.9 ± 44.5 nm; 5300 m 82.2 ± 20.2 nm; P = .019) and adiponectin (SL 10.4 ± 6.5 ng/mL, 4000 m 13.9 ± 8.5 ng/mL, 4750 m 18.3 ± 8.3 ng/mL, 5300 m 14.7 ± 8.0 ng/mL; P = .015) increased, as did insulin and Interleukin-6 (IL-6) levels (up to 71% and 168%, respectively; P < .05) with no change in leptin, complement C3 (C3), high sensitivity C-reactive protein (hsCRP) or cortisol levels throughout the mountain ascent from SL to 5300 m.ConclusionAcylation-stimulating protein and adiponectin are increased during a 9-day period of high altitude (SL to 5300 m) exposure despite weight loss in healthy mountaineers.